Opioid-induced constipation: advances and clinical guidance

A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population

(2016) Kathryn E. Mansfield et al.   PAIN

A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain

(2015) M Mazen Jamal et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Treatment With Prolonged-Release Oxycodone/Naloxone Improves Pain Relief and Opioid-Induced Constipation Compared With Prolonged-Release Oxycodone in Patients With Chronic Severe Pain and Laxative-Refractory Constipation

(2015) Jan Poelaert et al.   CLINICAL THERAPEUTICS

Definitions and Outcome Measures of Clinical Trials Regarding Opioid-induced Constipation

(2015) Jan Gaertner et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities

(2015) Alfred D. Nelson et al.   Therapeutic Advances in Gastroenterology

899 Td-1211 Phase 2B Study Demonstrates Increased Bowel Movement Frequency and Constipation-Related Symptom Improvement in Patients With Opioid Induced Constipation (OIC)

(2015) Ross G. Vickery et al.   GASTROENTEROLOGY

Site and mechanism of morphine tolerance in the gastrointestinal tract

(2015) H. I. Akbarali et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation

(2015) M. Camilleri et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation

(2014) L. Webster et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Differentiation between human ClC-2 and CFTR Cl− channels with pharmacological agents

(2014) John Cuppoletti et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives

(2014) Gineke Koopmans et al.   CURRENT MEDICAL RESEARCH AND OPINION

Oxycodone/Naloxone Prolonged-Release: A Review of Its Use in the Management of Chronic Pain While Counteracting Opioid-Induced Constipation

(2014) Celeste B. Burness et al.   DRUGS

The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol

(2014) Khanh Bui et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain

(2014) William D. Chey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers

(2014) David G. Soergel et al.   PAIN

A Randomized Study of Lubiprostone for Opioid-Induced Constipation in Patients with Chronic Noncancer Pain

(2014) Byron Cryer et al.   PAIN MEDICINE

Opioid-Induced Constipation: Pathophysiology, Clinical Consequences, and Management

(2014) Lalit Kumar et al.   Gastroenterology Research and Practice

Naloxegol for the treatment of opioid-induced constipation

(2014) Jan Tack et al.   Expert Review of Gastroenterology & Hepatology

Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia

(2013) Eric S. Schiffhauer et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Evaluation of the Effect of Naloxegol on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT/QTc Study in Healthy Volunteers

(2013) Christer Gottfridsson et al.   CLINICAL THERAPEUTICS

First Clinical Experience With TRV130: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

(2013) David G. Soergel et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Bowel Function Index for Evaluating Constipation in Pain Patients: Definition of a Reference Range for a Non-Constipated Population of Pain Patients

(2013) MA Ueberall et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Structure–Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain

(2013) Xiao-Tao Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

TD-1211 demonstrates a durable increase in bowel movement frequency and return toward normal bowel function in a 5-week Ph2b Opioid-Induced Constipation (OIC) study

(2013) R. Vickery et al.   JOURNAL OF PAIN

The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity

(2013) Scott R. Armstrong et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation

(2013) Lynn Webster et al.   PAIN

Methadone but not Morphine Inhibits Lubiprostone-Stimulated Cl− Currents in T84 Intestinal Cells and Recombinant Human ClC-2, but not CFTR Cl− Currents

(2012) John Cuppoletti et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Lubiprostone Targets Prostanoid Signaling and Promotes Ion Transporter Trafficking, Mucus Exocytosis, and Contractility

(2012) Robert L. Jakab et al.   DIGESTIVE DISEASES AND SCIENCES

Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers

(2011) Kevin Smith et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Severe Defects in Absorptive Ion Transport in Distal Colons of Mice That Lack ClC-2 Channels

(2011) Marcelo A. Catalán et al.   GASTROENTEROLOGY

A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/013) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain

(2011) Gordon Irving et al.   JOURNAL OF PAIN

Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Patients With Chronic, Nonmalignant Pain: A Randomized Controlled Study

(2011) Edward Michna et al.   JOURNAL OF PAIN

Efficacy of Subcutaneous Methylnaltrexone in the Treatment of Opioid-Induced Constipation: A Responder Post Hoc Analysis

(2011) Edward Michna et al.   PAIN MEDICINE

Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms

(2011) Shrividya S. Iyer et al.   VALUE IN HEALTH

The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health

(2010) B. S. Wong et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Validation of a Bowel Function Diary for Assessing Opioid-Induced Constipation

(2010) Michael Camilleri et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation

(2010) Cornelius E. J. Sloots et al.   DIGESTIVE DISEASES AND SCIENCES

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain

(2010) A. Sandner-Kiesling et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Methylnaltrexone and Gastrointestinal Perforation

(2010) Ann Corken Mackey et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract

(2010) Alexander P. Bryant et al.   LIFE SCIENCES

5-HT4 receptor agonists: similar but not the same

(2010) J. H. De Maeyer et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain

(2010) a. k. tuteja et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial

(2009) O Löwenstein et al.   EXPERT OPINION ON PHARMACOTHERAPY

Activation of Intestinal Cl− Secretion by Lubiprostone Requires the Cystic Fibrosis Transmembrane Conductance Regulator

(2009) Marcel J.C. Bijvelds et al.   GASTROENTEROLOGY

Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain

(2009) Roger Chou et al.   JOURNAL OF PAIN

Long-Acting Opioids and Short-Acting Opioids: Appropriate Use in Chronic Pain Management

(2009) Perry G. Fine et al.   PAIN MEDICINE

Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation

(2009) A. M. Rentz et al.   JOURNAL OF MEDICAL ECONOMICS

A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation

(2008) Winfried Meissner et al.   EUROPEAN JOURNAL OF PAIN

Analgesic Efficacy and Safety of Oxycodone in Combination With Naloxone as Prolonged Release Tablets in Patients With Moderate to Severe Chronic Pain

(2008) Dana Vondrackova et al.   JOURNAL OF PAIN

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain

(2008) Lynn Webster et al.   PAIN

The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)

(2008) Timothy J. Bell et al.   PAIN MEDICINE

The Fifth Vital Sign-What Does It Mean?

(2008) Mohammad Sami Walid et al.   Pain Practice